Daniela Califano
YOU?
Author Swipe
View article: The immunotherapy era in ovarian clear cell carcinoma: current evidence and future perspective
The immunotherapy era in ovarian clear cell carcinoma: current evidence and future perspective Open
Ovarian clear cell carcinoma (OCCC) is a rare, aggressive epithelial ovarian cancer subtype, accounting for approximately 10% of cases and associated with a poor prognosis due to chemoresistance and unique tumor biology. OCCC is frequently…
View article: Multimodal ctDNA profiling identifies fragmentomics and tumor fraction as independent prognostic biomarkers of ovarian cancer survival: the MITO-16a/MANGO-OV2a trial experience
Multimodal ctDNA profiling identifies fragmentomics and tumor fraction as independent prognostic biomarkers of ovarian cancer survival: the MITO-16a/MANGO-OV2a trial experience Open
View article: Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer
Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer Open
Objectives: Endometrial cancer is the most common gynaecologic malignancy, and its mortality rate is rising. Advanced or recurrent disease remains challenging because historically there have been limited therapeutic options. We aim to desc…
View article: Using CCDC6 immunostaining in conjunction with the RAD51 HRD assay as a novel approach to expand PARPi treatment eligibility in HGSOC patients
Using CCDC6 immunostaining in conjunction with the RAD51 HRD assay as a novel approach to expand PARPi treatment eligibility in HGSOC patients Open
Purpose HGSOC patients with BRCA1/2 mutations show HRD and PARPi sensitivity. Notably, HRD and PARPi response can occur without BRCA mutations, suggesting other factors are involved. Loss of CCDC6 function can lead to HRD and PARPi sensiti…
View article: Programmed death‐ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV‐2 translational study
Programmed death‐ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV‐2 translational study Open
We are pleased to present our latest analyses, showing that multiple immunofluorescence (MIF) can be used in large multicenter clinical trials to define the prognostic/predictive value of programmed death-ligand 1 (PD-L1) by concomitantly …
View article: HR-SC—an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib
HR-SC—an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib Open
View article: Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial)
Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial) Open
View article: Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial Open
The study underscores the complexities of HRD assessment and advocates for a combined genomic and functional approach to enhance predictive accuracy in OvC treatment responses.
View article: The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells
The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells Open
The axis CXCL12-CXCR4 is highly expressed in ovarian cancer where contributes to disease progression. Aim of the work was to evaluate the effect of the newly developed CXCR4 antagonist R54 on human ovarian cancer cells aggressiveness. CXCL…
View article: Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial
Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial Open
Introduction In ovarian cancer, expression of metabolism-related markers has been investigated in several studies focusing on individual markers; however, a parallel quantitative evaluation of markers mapping to distinct metabolic processe…
View article: <scp>TP53</scp> mutations and survival in ovarian carcinoma patients receiving first‐line chemotherapy plus bevacizumab: Results of the <scp>MITO16A</scp>/<scp>MaNGO OV</scp>‐2 study
<span>TP53</span> mutations and survival in ovarian carcinoma patients receiving first‐line chemotherapy plus bevacizumab: Results of the <span>MITO16A</span>/<span>MaNGO OV</span>‐2 study Open
To date, there are no biomarkers that define a patient subpopulation responsive to bevacizumab (BEV), an effective treatment option for advanced ovarian carcinoma (OC). In the context of the MITO16A/MaNGO OV‐2 trial, a Phase IV study of ch…
View article: Data from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Data from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Purpose:To identify predictive factors of nivolumab sensitivity, peripheral blood NKs and regulatory T-cell (Treg) were evaluated in patients with metastatic renal cell carcinoma (mRCC) enrolled in the REVOLUTION trial.Experimental Design:…
View article: Supplementary Figure S13 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S13 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S13. T0-T1 values (after one month of nivolumab) between PD-1+ Tregs and Helios+Tregs in Responder and Not Responder patients
View article: Supplementary Figure S5 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S5 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S5. Nivolumab did not significantly affect peripheral NKs and Tregs
View article: Supplementary Figure S3 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S3 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S3. Pretreatment NKs and Tregs in mRCC-REV patients
View article: Supplementary Figure S11 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S11 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S11. HLA class I in primary RCC from REV patients
View article: Supplementary Figure S10 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S10 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S10. .632+ cross validation bootstrap ROC curves and the optimum T1 cut-off values of CD3+ and KIR2DL2/DL3+NKs to determine the outcome of REV patients
View article: Supplementary Tables S1-S12 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Tables S1-S12 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Table S1. Antibodies used for flow cytometry Supplementary Table S2. mRCC-REV patients characteristics Supplementary Table S3. HDs characteristics Supplementary Table S4. Representativeness of Study Participants Supplementary…
View article: Supplementary Figure S7 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S7 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S7. Pretreatment NKs and Tregs subpopulations in mRCC-REV Long Responder (LR) patients vs Not-Responders (NR).
View article: Supplementary Figure S12 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S12 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S12. Correlation between pretreatment of PD-1+Tregs and Helios+Tregs in Responder and Not-Responder patients.
View article: Supplementary Figure S6 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S6 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S6. Swimmer’s plot of nivolumab-treated mRCC patients.
View article: Supplementary Figure S4 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S4 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S4. Pretreatment NKs co-expression of PD-1 and KIR2DL1or KIR2DL2/DL3 in mRCC-REV patients.
View article: Supplementary Figure S1 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S1 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S1. Gating strategy for identification of Tregs and NKs in peripheral blood.
View article: Supplementary Figure S8 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S8 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S8. .632+ cross validation bootstrap ROC curves and the optimum pretreatment cut-off values of KIR2DL2/DL3+NKs and Helios+Tregs to determine the outcome of REV patients
View article: Supplementary Figure S2 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S2 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S2. Correlation between age and pretreatment NKs and Tregs immune subsets cells in mRCC-REV patients and HDs.
View article: Supplementary Figure S9 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S9 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S9. Association between the KIR2DL2/DL3+NKs/Helios+Tregs values and response to nivolumab treatment.
View article: KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Purpose: To identify predictive factors of nivolumab sensitivity, peripheral blood NKs and regulatory T-cell (Treg) were evaluated in patients with metastatic renal cell carcinoma (mRCC) enrolled in the REVOLUTION trial. Experimental Desig…
View article: 47MO The risk index of early relapse defined by MiROvaR, a miRNA-based classifier, is a potential predictive marker for bevacizumab benefit: A MITO-MANGO-ENGOT study
47MO The risk index of early relapse defined by MiROvaR, a miRNA-based classifier, is a potential predictive marker for bevacizumab benefit: A MITO-MANGO-ENGOT study Open
The introduction of PARP inhibitors (PARPi) has greatly changed Ovarian Cancer (OC) patients' journey. Nonetheless, subgroups of patients still benefit of Bevacizumab (Bev) particularly those at clinical high risk or proficient for BRCA an…
View article: MITO END-3: efficacy of Avelumab immunotherapy according to molecular profiling in first line endometrial cancer therapy
MITO END-3: efficacy of Avelumab immunotherapy according to molecular profiling in first line endometrial cancer therapy Open
Immunotherapy combined to chemotherapy significantly improves progression free survival compared to first line chemotherapy alone in advanced endometrial cancer, with a much larger effect size in microsatellite-instability high (MSI-H) cas…
View article: MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy Open